Cargando…

Statin Intolerance: an Overview of US and International Guidance

PURPOSE OF REVIEW: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS). RECENT FINDINGS: Multiple organizations around the world have produced guidance documents to aid cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheeley, Mary Katherine, Clegg, Katarina, Lockridge, Connor, Schubert, Tyler J., Jones, Laney K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412662/
https://www.ncbi.nlm.nih.gov/pubmed/37410332
http://dx.doi.org/10.1007/s11883-023-01124-z
_version_ 1785086962301927424
author Cheeley, Mary Katherine
Clegg, Katarina
Lockridge, Connor
Schubert, Tyler J.
Jones, Laney K.
author_facet Cheeley, Mary Katherine
Clegg, Katarina
Lockridge, Connor
Schubert, Tyler J.
Jones, Laney K.
author_sort Cheeley, Mary Katherine
collection PubMed
description PURPOSE OF REVIEW: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS). RECENT FINDINGS: Multiple organizations around the world have produced guidance documents to aid clinicians on managing statin intolerance. A common theme resides among all the guidance documents that most patients can tolerate statins. For those patients who cannot, healthcare teams need to evaluate, rechallenge, educate, and ensure adequate reduction of atherogenic lipoproteins. SUMMARY: Statin therapy remains the cornerstone of lipid-lowering therapies to reduce atherosclerotic cardiovascular disease (ASCVD) and reduce mortality and morbidity. The common theme throughout all these guidance documents is the importance of statin therapy to reduce ASCVD and continual adherence to treatment. Because adverse events occur and inhibit patients from achieving adequate lowering of their atherogenic lipoproteins, trial and rechallenge of statin therapy, as well as addition of non-statin therapies, especially in high-risk patients, is also undisputed. The main differences stem from laboratory monitoring and the classification of the severity of the adverse effect. Future research should focus on consistently diagnosing SAMS so that these patients can be easily identified in the electronic health records.
format Online
Article
Text
id pubmed-10412662
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-104126622023-08-11 Statin Intolerance: an Overview of US and International Guidance Cheeley, Mary Katherine Clegg, Katarina Lockridge, Connor Schubert, Tyler J. Jones, Laney K. Curr Atheroscler Rep Article PURPOSE OF REVIEW: To review recent international and domestic definitions, considerations, and treatment algorithms for statin intolerance, and specifically, statin-associated muscle symptoms (SAMS). RECENT FINDINGS: Multiple organizations around the world have produced guidance documents to aid clinicians on managing statin intolerance. A common theme resides among all the guidance documents that most patients can tolerate statins. For those patients who cannot, healthcare teams need to evaluate, rechallenge, educate, and ensure adequate reduction of atherogenic lipoproteins. SUMMARY: Statin therapy remains the cornerstone of lipid-lowering therapies to reduce atherosclerotic cardiovascular disease (ASCVD) and reduce mortality and morbidity. The common theme throughout all these guidance documents is the importance of statin therapy to reduce ASCVD and continual adherence to treatment. Because adverse events occur and inhibit patients from achieving adequate lowering of their atherogenic lipoproteins, trial and rechallenge of statin therapy, as well as addition of non-statin therapies, especially in high-risk patients, is also undisputed. The main differences stem from laboratory monitoring and the classification of the severity of the adverse effect. Future research should focus on consistently diagnosing SAMS so that these patients can be easily identified in the electronic health records. Springer US 2023-07-06 2023 /pmc/articles/PMC10412662/ /pubmed/37410332 http://dx.doi.org/10.1007/s11883-023-01124-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Cheeley, Mary Katherine
Clegg, Katarina
Lockridge, Connor
Schubert, Tyler J.
Jones, Laney K.
Statin Intolerance: an Overview of US and International Guidance
title Statin Intolerance: an Overview of US and International Guidance
title_full Statin Intolerance: an Overview of US and International Guidance
title_fullStr Statin Intolerance: an Overview of US and International Guidance
title_full_unstemmed Statin Intolerance: an Overview of US and International Guidance
title_short Statin Intolerance: an Overview of US and International Guidance
title_sort statin intolerance: an overview of us and international guidance
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412662/
https://www.ncbi.nlm.nih.gov/pubmed/37410332
http://dx.doi.org/10.1007/s11883-023-01124-z
work_keys_str_mv AT cheeleymarykatherine statinintoleranceanoverviewofusandinternationalguidance
AT cleggkatarina statinintoleranceanoverviewofusandinternationalguidance
AT lockridgeconnor statinintoleranceanoverviewofusandinternationalguidance
AT schuberttylerj statinintoleranceanoverviewofusandinternationalguidance
AT joneslaneyk statinintoleranceanoverviewofusandinternationalguidance